<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(6)</volume><submitter>Sarwar S</submitter><pubmed_abstract>A targeted delivery system is primarily intended to carry a potent anticancer drug to specific tumor sites within the bodily tissues. In the present study, a carrier system has been designed using folic acid (FA), bis-amine polyethylene glycol (PEG), and an anticancer drug, 5-fluorouracil (5-FU). FA and PEG were joined via an amide bond, and the resulting FA-PEG-NH&lt;sub>2&lt;/sub> was coupled to 5-FU producing folate-polyethylene glycol conjugated 5-fluorouracil (FA-PEG-5-FU). Spectroscopic techniques (UV-Vis, &lt;sup>1&lt;/sup>HNMR, FTIR, and HPLC) were used for the characterization of products. Prodrug (FA-PEG-5-FU) was analyzed for drug release profile (in vitro) up to 10 days and compared to a standard anticancer drug (5-FU). Folate conjugate was also analyzed to study its folate receptors (FR) </pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pagination>1780</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8954791</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Folate Conjugated Polyethylene Glycol Probe for Tumor-Targeted Drug Delivery of 5-Fluorouracil.</pubmed_title><pmcid>PMC8954791</pmcid><pubmed_authors>Sarwar S</pubmed_authors><pubmed_authors>Abdul Qadir M</pubmed_authors><pubmed_authors>Ahmad S</pubmed_authors><pubmed_authors>Vanmeert M</pubmed_authors><pubmed_authors>Alharthy RD</pubmed_authors><pubmed_authors>Ahmed M</pubmed_authors><pubmed_authors>Mirza MU</pubmed_authors><pubmed_authors>Hameed A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Folate Conjugated Polyethylene Glycol Probe for Tumor-Targeted Drug Delivery of 5-Fluorouracil.</name><description>A targeted delivery system is primarily intended to carry a potent anticancer drug to specific tumor sites within the bodily tissues. In the present study, a carrier system has been designed using folic acid (FA), bis-amine polyethylene glycol (PEG), and an anticancer drug, 5-fluorouracil (5-FU). FA and PEG were joined via an amide bond, and the resulting FA-PEG-NH&lt;sub>2&lt;/sub> was coupled to 5-FU producing folate-polyethylene glycol conjugated 5-fluorouracil (FA-PEG-5-FU). Spectroscopic techniques (UV-Vis, &lt;sup>1&lt;/sup>HNMR, FTIR, and HPLC) were used for the characterization of products. Prodrug (FA-PEG-5-FU) was analyzed for drug release profile (in vitro) up to 10 days and compared to a standard anticancer drug (5-FU). Folate conjugate was also analyzed to study its folate receptors (FR) </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2026-04-08T17:46:48.976Z</modification><creation>2025-04-05T15:22:34.868Z</creation></dates><accession>S-EPMC8954791</accession><cross_references><pubmed>35335144</pubmed><doi>10.3390/molecules27061780</doi></cross_references></HashMap>